Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

AALNYLAM PHARMACEUTICALS, INC.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
A

ALNYLAM PHARMACEUTICALS, INC.

$251.65Close · Sep 22, 2026
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • History
  • Insider Transactions
Loading financials
Income statement income statement flow. Revenue $1.29B. Net result $164.49M.

Income statement revenue $1.29B (+66.9% YoY).Operating income $231.44M.Pre-tax result $177.81M.Net result $164.49M.

  • Amvuttra: $1.01B (+105.7% YoY)
  • Collaborations: $47.17M (-23.3% YoY)
  • GIVLAARI: $89.76M (+11.0% YoY)
  • ONPATTRO: $18.46M (-64.9% YoY)
  • OXLUMO: $52.12M (+11.2% YoY)
  • Royalty: $71.67M (+79.3% YoY)
  • Cost of collaborations and royalties: $190K (-79.4% YoY)
  • Research and development: $413.13M (+27.7% YoY)
  • Selling, general and administrative: $347.92M (+7.6% YoY)
  • Other expense: $53.64M (+113.6% YoY)
  • Income tax expense: $13.31M (-56.9% YoY)